![]() ![]() Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only. The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document. Volition's research and development activities are centered in Belgium, with a small laboratory in California and additional offices in Texas, London and Singapore, as the company focuses on bringing its diagnostic products to market.įor more information about Volition, visit Volition's website or connect with us via: Volition is primarily focused on human diagnostics but also has a subsidiary focused on animal diagnostics. The tests are based on the science of Nucleosomics TM, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life. Volition is a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases. Butera received his Bachelor of Arts degree from Fairfield University and his DVM from the University of Missouri Veterinary School. Butera's vast industry experiences includes serving as Co-Founder, Board Member and Chief Medical Officer of Pet Partners, LLC, which was acquired by Mars Veterinary Health in 2016. Butera has resigned from his positions as a non- executive member of the Board of Directors and related Committees of Volition in anticipation of taking up this executive role. Butera will continue to serve in his current role of Business Development Director at Veterinary Centers of America (VCA), part of Mars Veterinary Health, before assuming the new CEO position with Volition Veterinary on May 1st.Įffective immediately, Dr. "I am looking forward to reviewing the Texas beta launch, conducting the Asian and European beta launches and, most importantly, establishing the sales and distribution model for Nu.Q® Vet products worldwide, including licensing and distribution discussions with large multinational Veterinary companies."ĭr. "My vision for Volition Veterinary is to ensure the Nu.Q® Vet Cancer Screening Wellness Test and all subsequent products become the 'first line cancer diagnostic of choice' for small and large animal veterinarians, firstly in the U.S. "This is a key time for Volition Veterinary as the beta launch in Texas continues to facilitate real-world learnings which will help shape the marketing mix before our planned launch nationally across the U.S. Tom is a proven entrepreneur, innovator and value-based leader in the veterinary healthcare field, and we are confident he will bring a deep scientific understanding, as well as valuable strategic, operational and management experience to the role," commented Cameron Reynolds, Group Chief Executive Officer, of Volition. "We are delighted that Tom has agreed to lead our Veterinary subsidiary. Gaetan Michel who continues to serve as Chief Operating Officer of Volition and Chief Executive Officer of Belgian Volition. Tom Butera DVM, to the position of Chief Executive Officer, Volition Veterinary Diagnostics Development LLC, assuming such role from Dr. AUSTIN, Texas, Ma/PRNewswire/ - VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, announced today the appointment, effective May 1, 2021, of Dr.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |